Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - NeoStem, Inc. (NBS-NYSE Amex) |
|
|
We have two sides of our business. We have a majority interest in a pharmaceutical company that produces over 100 drugs. 95% are antibiotic finished goods that are distributed throughout China. It is a very profitable business with over $60 million in revenue in 2009. It is a great platform for growth because China is going through healthcare reform and is putting $124 billion into healthcare over the next couple of years, increasing access points of care… - Dr. Robin L. Smith, M.D., MBA (NBS) (Interview published June 18, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
NEW
YORK, July 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.
Vincent Falanga, M.D., F.A.C.P., Professor, Boston University School of Medicine and Chairman and Program Director at Roger Williams Medical Center, who is to be Co-Principal Investigator for this study, endorsed Dr. Smith's statement adding, "Adult mesenchymal stem cells (MSCs) and very small embryonic-like (VSEL) stem cells can be harvested with relative ease from individuals. Our studies indicate that an individual's own (autologous) stem cells can be highly successful in healing wounded tissues and in regenerative processes. Together with the wound delivery methods we have developed, these stem cells could bring about a quantum step forward in the way we treat non-healing chronic wounds and many types of injuries, both in the civilian and military population."
About USAMRMC The USAMRMC is responsible for medical research, development, and acquisition and medical logistics management to establish and maintain the capabilities the Army needs to fight and win on the battlefield. For more information, please visit: https://mrmc-www.army.mil/
About TATRC TATRC performs medical reconnaissance and special operations to address critical gaps that are underrepresented in DoD medical research programs and, among other objectives, aims to invest in and manage research projects and programs that will benefit service members with traumatic injuries by restoring them to fullest possible function. For more information, please visit: http://www.tatrc.org/?p=home
About NeoStem, Inc. NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL(TM) Technology and adult stem cells as a viable treatment option and whether any government funding will be available for any future projects, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's prospectus filed with the Securities and Exchange Commission on June 28, 2010 under Rule 424(b)(5), as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact:
CCG Investor Relations, Inc. Kalle Ahl, Account Manager Phone: +1-646-833-3417 Email: kalle.ahl@ccgir.com
Crocker Coulson, President Phone: +1-646-213-1915 Email: crocker.coulson@ccgir.com
SOURCE NeoStem, Inc.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.